• Capex and expansion: Symbiotec Pharmalab has invested over ₹850 crore to build two new growth engines in fermentation-based CDMO and complex injectables, expanding its gross block to around ₹1,100 crore.
• Revenue commercialization timeline: Fermentation CDMO revenues will start kicking in during the current fiscal year, while complex injectables revenue will begin in the next fiscal year, with sales expected to ramp up to optimal levels over 3 to 4 years.
• Long-term revenue mix: Over the next 5 to 7 years, management anticipates the revenue contribution to evolve from being almost entirely API-driven to approximately 40% from base API and about 30% each from the two new verticals.
• Margin expansion outlook: While the current base business operates at 60% to 65% gross margins, the new specialized verticals are expected to follow industry benchmarks of 70% to 75% gross margins and 35% to 45% EBITDA margins.